USRM.. from a charting persepctive, you wouldnt create a

New Post Public Reply Private Reply Replies (0) Message Board
joey68
154
USRM.. from a charting persepctive, you wouldnt create a position until you see todays close on the heikin ashi..

http://stockcharts.com/h-sc/ui?s=USRM&p=D...1149446507

we would need a third red filled candle to confirm a high possibility of a price drop

Not investment advice. i am not invested in USRM.
View My Board Here:
http://investorshangout.com/Joeys-Investment-Board-91611/


Invite Only

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.

Disclaimer:
As used herein, the terms "You" and "Your" shall mean you, individually, the reader, and each other party on whose behalf you may use the contained information at any time.
All references to "My", "I", and “The writer of the above post” shall refer to the creator of the username Joey68.

Do NOT invest unless you are prepared to sustain a total loss of the money you have invested plus any commission or other transaction charges.

There is a very high degree of risk involved in trading and investing. Past results are not indicative of future returns. I assume no responsibility for your trading and investment results. You should NOT rely on the information in the above post to make any decision or take any action.

ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are OPINION and NOT fact and are for entertainment purposes only. Do your own research and make your own decisions based on your own conclusions.
ALL OF MY STATEMENTS, including but not limited to, POSTS, MESSAGES, PRIVATE MESSAGES, and RESPONSES are NOT advice, and are NOT designed to substitute the expertise and judgment of a professional. It is your responsibility to seek investment advice during all stages of your investments. It is your responsibility to evaluate the accuracy, completeness and usefulness of the information in the above post.
I am NOT a professional.
I do NOT work for you.
My posts are NOT investment advice. I am not paid to post.
There is no correlation between the number of posts I write per day and your assumed success of a company.
It is NOT my responsibility to inform you of my own personal investment decisions.
It is NOT my responsibility to inform you when it is time for you to buy, hold, and/or sell a position.
I have no control over, and am not responsible for the actions of others who copy, store, edit, change, prepare any derivative work of or alter in any way any of the content provided in my posts.
Errors and Omissions expected. The writer of the above post accepts no liability or responsibility for any errors or omissions contained in the above post or contained within this Disclaimer.
The writer of the above post shall NOT accept any liability for the accuracy or completeness of the information contained in the above post, for any reliance placed by any person on the information contained in the above post, or for any damage or loss, however caused, in connection with the use or reliance on any information contained in the above post.
The above post may contain links to websites owned and operated by third parties. These links are provided for informational purposes only and are NOT endorsed by the writer of the above post. The writer of the above post has no control over the contents of any linked website and bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links.
YOU ACCESS ALL LINKS ENTIRELY AT YOUR OWN RISK.
The writer of the above post makes no warranties or representations, express or implied about such linked websites, the third parties they are owned and operated by, or the information contained on these websites.
The writer of the above post accepts no liability for any damage or loss, however caused, in connection with the use of or reliance on any information, material, products, or services contained on or accessed through any such linked websites.

There is a VERY HIGH degree of RISK involved in trading and investing. Only invest what you can afford to lose.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cancer Memoir Shows Healing Beyond Medicine

Updated Category News Views 0

Confronting the Unfathomable Out of the North Carolina mountains comes a story that defies expectations—a pastor and farmer named Mark Heisey, who faced the no-holds-barred trials of stage IV-B lymphoma. Now, I'll shoot you straight: this isn't your run-of-the-mill self-help guide or a clinical breakdown of battling cancer. His new memoir dives into the personal and...

Continue Reading
AEVEX Facing Class Action: Deadline Looms for Investors

Updated Category News Views 0

The Clock is Ticking for AVEX Investors News flash, folks: If you bought into AEVEX Corp. (NYSE: AVEX) between mid-April and early June this year, you might have a legal gold mine on your hands—or at least a shot to join a class action that could knock some dollars back into your pocket. Mark it on your calendar—October 20, 2026, is the last call to toss your hat in...

Continue Reading
Richard Huffman Joins IFA Board, Strengthens Franchise Ties

Updated Category News Views 2

Ever wonder how the cogs in this massive machine called franchising keep turning? It's folks like Richard Huffman who step up to the plate, and his recent election to the International Franchise Association (IFA) Board of Directors is worth a second glance. Huffman: A Franchise Veteran Now, Huffman isn't some rookie in the world of franchising. You see, back in '94, he...

Continue Reading
Venue Two Eleven: Historic Charm Meets Modern Events

Updated Category News Views 0

Welcome To Venue Two Eleven: Where History Meets Modernity Alright, folks. Let’s talk about Venue Two Eleven—a new joint in town that’s blending the old with the new in a way that’s got me raising an eyebrow and maybe even sipping my coffee a little slower. Nestled in the Museum of the Oregon Territory, this place is pulling double duty as both a window to the...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 65

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 33

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
GELITA Showcases Collagen Innovations at SupplySide 2026

Updated Category News Views 0

Collagen Solutions Front and Center First up, a little chat about collagen might be in order. For folks not tied into the science side, it sounds like a trendy wellness potion. But here comes GELITA at SupplySide Global 2026, showing it's the real McCoy. Nestled in Booth #4565, they're laying out a spread of next-gen collagen innovations aimed at everything from wound...

Continue Reading
U.S. Millionaire Surge: Market Waves or Mirage?

Updated Category News Views 0

Flashing Billions: Minting Millionaires at Breakneck Speed It sounds like something out of an 80s movie: every single day, over 1,200 folks in the United States become millionaires. Yep, you heard right. The UBS Global Wealth Report 2026 threw that number out, and it sure caught my attention. It's not everyday you hear about the U.S. cranking out millionaires like they're...

Continue Reading
Kansai Medical Ushers in New Era of Cancer Research

Updated Category News Views 1

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

Continue Reading
Match2 Enhances HR Tech: Unified Talent Profile System

Updated Category News Views 1

Revolutionizing Talent Matching with Match2's Latest Upgrades In the churn of today's recruiting jungle, candidates and employers have been grappling with disjointed systems and outdated approaches. Well, Match2 is cutting through that noise with some hefty upgrades. It's got some new toys in the shed—specifically, a beefed-up Universal Candidate Profile™ and an...

Continue Reading

Top 5 Most Recently Viewed Articles

Securiti Earns Noteworthy AWS Security Competency in AI

Updated Category News Views 375

Securiti Achieves AWS Security Competency Status in AI Security Securiti, the pioneer of the Data+AI Command Center, proudly announces its recent achievement of Amazon Web Services (AWS) Security Competency status in the innovative AI Security category. This new milestone highlights Securiti as one of the select inaugural partners recognized by AWS for its exceptional...

Continue Reading
Exciting Family Medicine Forum in Winnipeg This Fall

Updated Category News Views 204

Join the Family Medicine Forum in Winnipeg Mark your calendars, as the Family Medicine Forum is heading to Winnipeg this November for an enriching experience that promises to bring together family physicians from across the nation. This premier event is not only a chance to learn but to celebrate the vital work family doctors do every day. The Essence of Family Medicine...

Continue Reading
Man Group PLC Reveals Interest in Dowlais Group Securities

Updated Category News Views 106

Understanding the Disclosure by Man Group PLC In the realm of financial markets, disclosures play a crucial role in maintaining transparency and informing stakeholders about significant market movements. Recently, Man Group PLC made headlines by revealing its position regarding Dowlais Group PLC's relevant securities. This disclosure is essential as it reflects the...

Continue Reading
Experity Welcomes Bobby Ghoshal as New COO and President

Updated Category News Views 371

Experity Welcomes Bobby Ghoshal as President and COO Experity, a leader in on-demand healthcare solutions, has appointed Bobby Ghoshal as its new President and Chief Operating Officer. In this important role, Mr. Ghoshal will spearhead daily operations, steering the strategic direction for the company. His appointment is pivotal in enhancing Experity's mission to serve...

Continue Reading
LifeMD's Upcoming Engagements at Major Investor Conferences

Updated Category News Views 96

LifeMD's Upcoming Engagements at Major Investor Conferences LifeMD, Inc. (Nasdaq: LFMD), a trailblazer in virtual primary care, has recently announced its participation in several prominent investor conferences this September. As a company recognized for its innovative approach in telemedicine, LifeMD’s management is eager to showcase their vision and accomplishments to...

Continue Reading